drugset / Trial / NCT06413654
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
Phase 2/3
Recruiting
132 enrolled
Shanghai Jiaolian Drug Research and Development Co., Ltd
Shanghai Pharmaceuticals Holding Co., Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.
Timeline
- Start
- 2024-07-17
- Primary completion
- 2027-10-31
- Completion
- 2029-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B001 | Monoclonal antibody | — | Intravenous |